Cargando…

Barriers of Doctors and Patients in Starting Insulin for Type 2 Diabetes Mellitus

Background Management of patients with type 2 diabetes mellitus (T2DM) may involve insulin therapy. However, this treatment may be avoided or delayed by physicians or patients due to the presence of certain barriers. This study aimed to evaluate the barriers to initiating insulin therapy for both ph...

Descripción completa

Detalles Bibliográficos
Autores principales: Alidrisi, Haider A, Bohan, Ali, Mansour, Abbas A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8543092/
https://www.ncbi.nlm.nih.gov/pubmed/34712538
http://dx.doi.org/10.7759/cureus.18263
_version_ 1784589569071513600
author Alidrisi, Haider A
Bohan, Ali
Mansour, Abbas A
author_facet Alidrisi, Haider A
Bohan, Ali
Mansour, Abbas A
author_sort Alidrisi, Haider A
collection PubMed
description Background Management of patients with type 2 diabetes mellitus (T2DM) may involve insulin therapy. However, this treatment may be avoided or delayed by physicians or patients due to the presence of certain barriers. This study aimed to evaluate the barriers to initiating insulin therapy for both physicians and patients with T2DM.  Method This was a cross-sectional, questionnaire-based study. Data related to the physicians’ personal and professional experience were collected, and 15 barriers to initiating insulin therapy were scored by each physician on a four-point Likert scale. Also, the patients’ general data were collected, including previous insulin experience, discontinuation reason, and willingness to start insulin therapy if indicated. Twenty-one other barriers were examined with yes/no questions as well. Results For physicians, the patient's treatment compliance, motive, dependence on others for insulin therapy, hypoglycemia, socioeconomic status, occupation, and lack of follow-up were the most highly ranked barriers to initiating insulin therapy. A history of insulin use was reported in 42 (20.7%) patients, 31 of whom had decided to discontinue insulin therapy themselves (73.8%). The three most common reasons for discontinuing insulin therapy among patients were deterioration of T2DM and causing complications, hypoglycemia, and needle injections. Based on the findings, 99 (48.8%) patients were willing to start insulin therapy, if indicated. The family history of insulin therapy was positively correlated with the patient’s willingness to start insulin. On the other hand, it was negatively correlated with a low educational level and some barriers to insulin therapy, such as fear of death, dependence on others, the difficulty of carrying insulin while traveling, follow-up challenges, the difficulty of dosing accuracy, the difficulty of keeping insulin, inconveniences in daily life, considering insulin as the last resort, the deterioration of T2DM with insulin, and social stigma. Conclusion The physicians believed that the barriers to initiating insulin therapy were mainly related to the patient's attitudes and thoughts about this therapy. While hypoglycemia and weight gain are well-known side effects of insulin therapy, the most important patient-related barriers to insulin therapy were related to its impact on the patient’s social life and misperceptions about the side effects of insulin.
format Online
Article
Text
id pubmed-8543092
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-85430922021-10-27 Barriers of Doctors and Patients in Starting Insulin for Type 2 Diabetes Mellitus Alidrisi, Haider A Bohan, Ali Mansour, Abbas A Cureus Endocrinology/Diabetes/Metabolism Background Management of patients with type 2 diabetes mellitus (T2DM) may involve insulin therapy. However, this treatment may be avoided or delayed by physicians or patients due to the presence of certain barriers. This study aimed to evaluate the barriers to initiating insulin therapy for both physicians and patients with T2DM.  Method This was a cross-sectional, questionnaire-based study. Data related to the physicians’ personal and professional experience were collected, and 15 barriers to initiating insulin therapy were scored by each physician on a four-point Likert scale. Also, the patients’ general data were collected, including previous insulin experience, discontinuation reason, and willingness to start insulin therapy if indicated. Twenty-one other barriers were examined with yes/no questions as well. Results For physicians, the patient's treatment compliance, motive, dependence on others for insulin therapy, hypoglycemia, socioeconomic status, occupation, and lack of follow-up were the most highly ranked barriers to initiating insulin therapy. A history of insulin use was reported in 42 (20.7%) patients, 31 of whom had decided to discontinue insulin therapy themselves (73.8%). The three most common reasons for discontinuing insulin therapy among patients were deterioration of T2DM and causing complications, hypoglycemia, and needle injections. Based on the findings, 99 (48.8%) patients were willing to start insulin therapy, if indicated. The family history of insulin therapy was positively correlated with the patient’s willingness to start insulin. On the other hand, it was negatively correlated with a low educational level and some barriers to insulin therapy, such as fear of death, dependence on others, the difficulty of carrying insulin while traveling, follow-up challenges, the difficulty of dosing accuracy, the difficulty of keeping insulin, inconveniences in daily life, considering insulin as the last resort, the deterioration of T2DM with insulin, and social stigma. Conclusion The physicians believed that the barriers to initiating insulin therapy were mainly related to the patient's attitudes and thoughts about this therapy. While hypoglycemia and weight gain are well-known side effects of insulin therapy, the most important patient-related barriers to insulin therapy were related to its impact on the patient’s social life and misperceptions about the side effects of insulin. Cureus 2021-09-25 /pmc/articles/PMC8543092/ /pubmed/34712538 http://dx.doi.org/10.7759/cureus.18263 Text en Copyright © 2021, Alidrisi et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Endocrinology/Diabetes/Metabolism
Alidrisi, Haider A
Bohan, Ali
Mansour, Abbas A
Barriers of Doctors and Patients in Starting Insulin for Type 2 Diabetes Mellitus
title Barriers of Doctors and Patients in Starting Insulin for Type 2 Diabetes Mellitus
title_full Barriers of Doctors and Patients in Starting Insulin for Type 2 Diabetes Mellitus
title_fullStr Barriers of Doctors and Patients in Starting Insulin for Type 2 Diabetes Mellitus
title_full_unstemmed Barriers of Doctors and Patients in Starting Insulin for Type 2 Diabetes Mellitus
title_short Barriers of Doctors and Patients in Starting Insulin for Type 2 Diabetes Mellitus
title_sort barriers of doctors and patients in starting insulin for type 2 diabetes mellitus
topic Endocrinology/Diabetes/Metabolism
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8543092/
https://www.ncbi.nlm.nih.gov/pubmed/34712538
http://dx.doi.org/10.7759/cureus.18263
work_keys_str_mv AT alidrisihaidera barriersofdoctorsandpatientsinstartinginsulinfortype2diabetesmellitus
AT bohanali barriersofdoctorsandpatientsinstartinginsulinfortype2diabetesmellitus
AT mansourabbasa barriersofdoctorsandpatientsinstartinginsulinfortype2diabetesmellitus